Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 2, Pages e88472
Publisher
Public Library of Science (PLoS)
Online
2014-02-07
DOI
10.1371/journal.pone.0088472
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study
- (2013) Neetu Agashivala et al. BMC Neurology
- Medical and Pharmacy Claims-Based Algorithms for Identifying Relapses in Patients with Multiple Sclerosis
- (2013) G. Capkun-Niggli et al. VALUE IN HEALTH
- Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod
- (2012) N.S. Roskell et al. CURRENT MEDICAL RESEARCH AND OPINION
- Early tolerability and safety of fingolimod in clinical practice
- (2012) Daniel Ontaneda et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence
- (2012) G Giovannoni et al. Multiple Sclerosis Journal
- Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study
- (2011) Jay M Margolis et al. BMC Neurology
- Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study
- (2011) Bhupendra Khatri et al. LANCET NEUROLOGY
- Current Disease-Modifying Treatment of Multiple Sclerosis
- (2011) Joy Derwenskus MOUNT SINAI JOURNAL OF MEDICINE
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
- (2011) Peter C. Austin MULTIVARIATE BEHAVIORAL RESEARCH
- Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis
- (2011) M. P. Sormani et al. NEUROLOGY
- Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis
- (2011) Rachel Halpern et al. Patient Preference and Adherence
- Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis
- (2010) Hiangkiat Tan et al. ADVANCES IN THERAPY
- Impact of Adherence to Interferons in the Treatment of Multiple Sclerosis
- (2010) Stephanie C. Steinberg et al. CLINICAL DRUG INVESTIGATION
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs
- (2010) Matthew W. Reynolds et al. JOURNAL OF MEDICAL ECONOMICS
- Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims
- (2010) Benjamin J. Chastek et al. JOURNAL OF MEDICAL ECONOMICS
- Dose response to interferon therapy in multiple sclerosis: an evaluation of the evidence
- (2009) S. Mitchell Freedman CURRENT MEDICAL RESEARCH AND OPINION
- Impact of Co-Prescribed Glatiramer Acetate and Antihistamine Therapy on the Likelihood of Relapse Among Patients with Multiple Sclerosis
- (2009) Daniel A. Ollendorf et al. JOURNAL OF NEUROSCIENCE NURSING
- 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
- (2009) Paul O'Connor et al. LANCET NEUROLOGY
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
- (2008) Erik von Elm et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
- (2008) Daniel D Mikol et al. LANCET NEUROLOGY
- Disease-modifying therapy in multiple sclerosis: Update and clinical implications
- (2008) D. S. Goodin NEUROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search